Pridinol
Pridinol is a centrally and peripherally acting muscle relaxant with anticholinergic properties, used for painful skeletal muscle spasm.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It relieves muscle spasm through antimuscarinic activity and central effects that reduce excessive muscle tone, rather than acting on a specific neuromuscular target.
Prescribing in practice
- Its anticholinergic action makes it unsuitable in conditions such as narrow-angle glaucoma, significant urinary retention, and certain gastrointestinal obstructive disorders, where it is contraindicated.
- It can cause drowsiness and impair driving and skilled-task performance, with additive sedation alongside alcohol and other CNS depressants.
- Caution is needed in older patients and those sensitive to anticholinergic effects such as dry mouth, blurred vision, and constipation.
Monitoring
Monitor for anticholinergic adverse effects and excessive sedation, particularly in older or susceptible patients.
Counselling the patient
- This medicine may make you drowsy; do not drive or operate machinery until you know how it affects you.
- Avoid alcohol, which can increase drowsiness.
- Tell your clinician about dry mouth, difficulty passing urine, or eye problems.
Evidence & guidelines
Pridinol is used as a skeletal muscle relaxant for painful muscle spasm based on established clinical use; consult current prescribing references for indication-specific guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022